Scarica l'app Stockscreener
12.58
0.08%
0.010
Precedente Chiudi:
$12.57
Aprire:
$12.64
Volume 24 ore:
794.42K
Relative Volume:
0.34
Capitalizzazione di mercato:
$807.94M
Reddito:
$161.10M
Utile/perdita netta:
$-308.60M
Rapporto P/E:
-2.6938
EPS:
-4.67
Flusso di cassa netto:
$-259.90M
1 W Prestazione:
-1.64%
1M Prestazione:
+20.85%
6M Prestazione:
+66.18%
1 anno Prestazione:
-36.27%
Intervallo 1D:
$12.47
$12.90
Intervallo di 1 settimana:
$12.47
$13.56
Portata 52W:
$5.90
$21.00
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Confronta ARVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
12.58 | 807.30M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-09-24 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-06-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Downgrade | Truist | Buy → Hold |
| 2025-05-02 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-02 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
Arvinas Inc (NASDAQ:ARVN) Nasdaq Composite Biotech Innovation - Kalkine Media
Velan Capital Investment Management LP Takes Position in Arvinas, Inc. $ARVN - MarketBeat
Diadema Partners LP Invests $710,000 in Arvinas, Inc. $ARVN - MarketBeat
Arvinas reveals promising preclinical data for ARV-393 - MSN
Arvinas Reveals Promising Preclinical Data for ARV-393 - TipRanks
Arvinas, Inc. Announces Preclinical Data for ARV-393 Combination - TradingView
22NW LP Acquires Shares of 413,533 Arvinas, Inc. $ARVN - MarketBeat
Arvinas (ARVN) Reveals Promising Preclinical Data for Cancer Tre - GuruFocus
Published on: 2025-12-06 23:24:37 - BỘ NỘI VỤ
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition - The Manila Times
Arvinas, Inc. Announces Phase 1 Clinical Trial Initiation for ARV-393 Plus Glofitamab in Diffuse Large B-Cell Lymphoma Following Promising Preclinical Data - Quiver Quantitative
Why Arvinas Inc. stock could benefit from AI revolutionProfit Target & AI Forecasted Stock Moves - Newser
Franklin Resources Inc. Grows Stake in Arvinas, Inc. $ARVN - MarketBeat
Why Arvinas Inc. stock is considered a top pickBear Alert & Momentum Based Trading Signals - Newser
ARVN: Robust clinical pipeline advances and strong cash position support growth into 2028 - TradingView
Will Arvinas Inc. stock continue upward momentumIPO Watch & Weekly Watchlist for Hot Stocks - Newser
Arvinas (ARVN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How the Narrative Around Arvinas Is Shifting Amid Strategic Moves and Analyst Uncertainty - Yahoo Finance
52,980 Shares in Arvinas, Inc. $ARVN Acquired by SG Americas Securities LLC - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN - The National Law Review
New Highs: Why Arvinas Inc. stock remains on buy listsJuly 2025 Update & Accurate Intraday Trade Tips - moha.gov.vn
Entropy Technologies LP Purchases Shares of 32,491 Arvinas, Inc. $ARVN - MarketBeat
Arvinas Inc Stock Analysis and ForecastLow Beta Stocks & Outstanding Investment Returns - earlytimes.in
Published on: 2025-11-27 09:33:44 - BỘ NỘI VỤ
Arvinas (Nasdaq: ARVN) plans fireside chat at Piper Sandler 37th Healthcare Conference - Stock Titan
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Arvinas to present vepdegestrant breast cancer data at SABCS By Investing.com - Investing.com Nigeria
Arvinas to present vepdegestrant breast cancer data at SABCS - Investing.com
Arvinas, Inc. Announces Multiple Abstract Presentations on Vepdegestrant at San Antonio Breast Cancer Symposium 2025 - Quiver Quantitative
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development ... - Enidnews.com
Arvinas Announces Data Presentations from the Vepdegestrant - GlobeNewswire
Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating (NASDAQ:ARVN) - Seeking Alpha
Promising Biotech Stocks To ConsiderNovember 18th - MarketBeat
Can Arvinas Inc. stock beat market expectations this quarterTrend Reversal & Fast Exit/Entry Strategy Plans - newser.com
Arvinas (NASDAQ:ARVN) Stock Price Down 7%Should You Sell? - MarketBeat
Why Arvinas Inc. stock attracts high net worth investorsRate Cut & High Win Rate Trade Tips - newser.com
Is Arvinas Inc. stock attractive after correctionJuly 2025 Technicals & Long-Term Safe Investment Ideas - newser.com
Connor Clark & Lunn Investment Management Ltd. Takes Position in Arvinas, Inc. $ARVN - MarketBeat
Arvinas Inc. stock chart pattern explainedSell Signal & Technical Pattern Recognition Alerts - newser.com
Is Arvinas Inc. still worth holding after the dipFed Meeting & Target Return Focused Stock Picks - newser.com
Arvinas Inc. (ARVN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Arvinas Inc. stock a top pick in earnings seasonJuly 2025 Earnings & Long-Term Safe Return Strategies - newser.com
Reversal indicators forming on Arvinas Inc. stockWeekly Stock Summary & AI Forecast Swing Trade Picks - newser.com
How Arvinas Inc. stock benefits from strong dollarForecast Cut & Real-Time Market Trend Scan - newser.com
Can Arvinas Inc. stock beat analyst upgradesQuarterly Performance Summary & Expert Curated Trade Ideas - newser.com
Arvinas (NASDAQ:ARVN) Shares Gap UpShould You Buy? - MarketBeat
Can technical indicators confirm Arvinas Inc.’s reversalJuly 2025 Macro Moves & Free Daily Entry Point Trade Alerts - newser.com
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arvinas Inc Azioni (ARVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Morrison Briggs | Director |
Sep 22 '25 |
Buy |
7.57 |
30,000 |
227,010 |
76,021 |
| Saik Andrew | Chief Financial Officer |
Jun 24 '25 |
Sale |
7.61 |
5,700 |
43,377 |
164,401 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):